Exciting Results from CRISPR Gene-Editing Therapy Trial for Heart Disease
A light micrograph cross-section showing cholesterol-containing plaque in a heart artery
NIGEL DOWNER/SCIENCE PHOTO LIBRARY
The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a personâs life just got brighter. In an initial trial, a single dose of a CRISPR gene-editing therapy lowered cholesterol levels without any serious side effects.
The âHeart-2â trial â organised by the biotech company Verve Therapeutics in Boston â involved 14 people who either had an inherited condition leading to very high cholesterol or had developed heart disease at a young age. While this was an early-stage trial…
